{"entity":{"id":"nct06525298","kind":"trial","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Olaparib and Trastuzumab deruxtecan in advanced solid tumours, run by Eisbach Bio GmbH, now recruiting.","summary":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors is a phase 1/2 interventional study registered as NCT06525298 by Eisbach Bio GmbH, with 144 participants planned, started 2024-09-09 and due to reach its primary completion in 2027-09. Interventions recorded: EIS-12656, Olaparib and Trastuzumab deruxtecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06525298","url":"https://clinicaltrials.gov/study/NCT06525298"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib","trastuzumab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06525298","phase":"1/2","setting":"A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors","sponsor":"Eisbach Bio GmbH","enrolled":144,"outcomes":[]},"route":"/trials/nct06525298/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}]}}